All In Biotech

Drug Trial Radar · NCT07768111

Clinical Study on Drug Interactions of Flonoltinib Maleate Tablets

A Single-Center, Open, Fixed-Sequence Clinical Drug Interaction Study Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetic Profile of Flonoltinib Maleate Tablets in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Dec 30, 2026

Study completion Jan 31, 2027

Sponsor

Sponsor type
Industry
First posted
Aug 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a single center, open label, fixed sequence drug interaction study to evaluate the effects of CYP3A4 inhibitor itraconazole and CYP3A4 inducer rifampicin on the pharmacokinetic characteristics of a single oral dose of flonotinib maleate tablets. This trial includes screening period, baseline period, medication observation period, and follow-up period, totaling approximately 3 months.

Conditions

  • Drug Interaction Research

Interventions

  • 75mg FlonoltinibDrug

    Day 1 and Day 12 : 75mg Flonoltinib on an empty stomach in the morning

  • 100mg FlonoltinibDrug

    Day 1 and Day 19 : 100mg Flonoltinib on an empty stomach in the morning

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: Until 144hours
  2. TmaxTime frame: Until 144hours
  3. AUC0-tTime frame: Until 144hours
  4. t1/2Time frame: Until 144hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.